These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25019571)

  • 1. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
    Powell MA; Sill MW; Goodfellow PJ; Benbrook DM; Lankes HA; Leslie KK; Jeske Y; Mannel RS; Spillman MA; Lee PS; Hoffman JS; McMeekin DS; Pollock PM
    Gynecol Oncol; 2014 Oct; 135(1):38-43. PubMed ID: 25019571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.
    Chan JK; Deng W; Higgins RV; Tewari KS; Bonebrake AJ; Hicks M; Gaillard S; Ramirez PT; Chafe W; Monk BJ; Aghajanian C
    Gynecol Oncol; 2017 Sep; 146(3):554-559. PubMed ID: 28728751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
    Aghajanian C; Sill MW; Darcy KM; Greer B; McMeekin DS; Rose PG; Rotmensch J; Barnes MN; Hanjani P; Leslie KK
    J Clin Oncol; 2011 Jun; 29(16):2259-65. PubMed ID: 21537039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Bender D; Sill MW; Lankes HA; Reyes HD; Darus CJ; Delmore JE; Rotmensch J; Gray HJ; Mannel RS; Schilder JM; Hunter MI; McCourt CK; Samuelson MI; Leslie KK
    Gynecol Oncol; 2015 Sep; 138(3):507-12. PubMed ID: 26186911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
    Alvarez EA; Brady WE; Walker JL; Rotmensch J; Zhou XC; Kendrick JE; Yamada SD; Schilder JM; Cohn DE; Harrison CR; Moore KN; Aghajanian C
    Gynecol Oncol; 2013 Apr; 129(1):22-7. PubMed ID: 23262204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.
    Makker V; Filiaci VL; Chen LM; Darus CJ; Kendrick JE; Sutton G; Moxley K; Aghajanian C
    Gynecol Oncol; 2015 Jul; 138(1):24-9. PubMed ID: 25888978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
    Coleman RL; Sill MW; Lankes HA; Fader AN; Finkler NJ; Hoffman JS; Rose PG; Sutton GP; Drescher CW; McMeekin DS; Hu W; Deavers M; Godwin AK; Alpaugh RK; Sood AK
    Gynecol Oncol; 2012 Dec; 127(3):538-43. PubMed ID: 22922531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
    Monk BJ; Sill MW; Burger RA; Gray HJ; Buekers TE; Roman LD
    J Clin Oncol; 2009 Mar; 27(7):1069-74. PubMed ID: 19139430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.
    Leslie KK; Sill MW; Fischer E; Darcy KM; Mannel RS; Tewari KS; Hanjani P; Wilken JA; Baron AT; Godwin AK; Schilder RJ; Singh M; Maihle NJ
    Gynecol Oncol; 2013 Jun; 129(3):486-94. PubMed ID: 23438670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.
    Jones RL; Ratain MJ; O'Dwyer PJ; Siu LL; Jassem J; Medioni J; DeJonge M; Rudin C; Sawyer M; Khayat D; Awada A; de Vos-Geelen JMPGM; Evans TRJ; Obel J; Brockstein B; DeGreve J; Baurain JF; Maki R; D'Adamo D; Dickson M; Undevia S; Geary D; Janisch L; Bedard PL; Abdul Razak AR; Kristeleit R; Vitfell-Rasmussen J; Walters I; Kaye SB; Schwartz G
    Eur J Cancer; 2019 Oct; 120():132-139. PubMed ID: 31522033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial.
    Kudo M; Han G; Finn RS; Poon RT; Blanc JF; Yan L; Yang J; Lu L; Tak WY; Yu X; Lee JH; Lin SM; Wu C; Tanwandee T; Shao G; Walters IB; Dela Cruz C; Poulart V; Wang JH
    Hepatology; 2014 Nov; 60(5):1697-707. PubMed ID: 24996197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.
    Coleman RL; Sill MW; Thaker PH; Bender DP; Street D; McGuire WP; Johnston CM; Rotmensch J
    Gynecol Oncol; 2015 Jul; 138(1):30-5. PubMed ID: 25887099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
    Finn RS; Kang YK; Mulcahy M; Polite BN; Lim HY; Walters I; Baudelet C; Manekas D; Park JW
    Clin Cancer Res; 2012 Apr; 18(7):2090-8. PubMed ID: 22238246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
    Burger RA; Sill MW; Monk BJ; Greer BE; Sorosky JI
    J Clin Oncol; 2007 Nov; 25(33):5165-71. PubMed ID: 18024863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
    Llovet JM; Decaens T; Raoul JL; Boucher E; Kudo M; Chang C; Kang YK; Assenat E; Lim HY; Boige V; Mathurin P; Fartoux L; Lin DY; Bruix J; Poon RT; Sherman M; Blanc JF; Finn RS; Tak WY; Chao Y; Ezzeddine R; Liu D; Walters I; Park JW
    J Clin Oncol; 2013 Oct; 31(28):3509-16. PubMed ID: 23980090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
    Leslie KK; Sill MW; Lankes HA; Fischer EG; Godwin AK; Gray H; Schilder RJ; Walker JL; Tewari K; Hanjani P; Abulafia O; Rose PG
    Gynecol Oncol; 2012 Nov; 127(2):345-50. PubMed ID: 22885469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
    Santin AD; Sill MW; McMeekin DS; Leitao MM; Brown J; Sutton GP; Van Le L; Griffin P; Boardman CH
    Gynecol Oncol; 2011 Sep; 122(3):495-500. PubMed ID: 21684583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
    Johnson PJ; Qin S; Park JW; Poon RT; Raoul JL; Philip PA; Hsu CH; Hu TH; Heo J; Xu J; Lu L; Chao Y; Boucher E; Han KH; Paik SW; Robles-Aviña J; Kudo M; Yan L; Sobhonslidsuk A; Komov D; Decaens T; Tak WY; Jeng LB; Liu D; Ezzeddine R; Walters I; Cheng AL
    J Clin Oncol; 2013 Oct; 31(28):3517-24. PubMed ID: 23980084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.
    McMeekin DS; Sill MW; Benbrook D; Darcy KM; Stearns-Kurosawa DJ; Eaton L; Yamada SD;
    Gynecol Oncol; 2007 May; 105(2):508-16. PubMed ID: 17306350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
    Konecny GE; Finkler N; Garcia AA; Lorusso D; Lee PS; Rocconi RP; Fong PC; Squires M; Mishra K; Upalawanna A; Wang Y; Kristeleit R
    Lancet Oncol; 2015 Jun; 16(6):686-94. PubMed ID: 25981814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.